261 related articles for article (PubMed ID: 10458617)
1. Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir.
Kravcik S; Gallicano K; Roth V; Cassol S; Hawley-Foss N; Badley A; Cameron DW
J Acquir Immune Defic Syndr; 1999 Aug; 21(5):371-5. PubMed ID: 10458617
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine.
Gisolf EH; Enting RH; Jurriaans S; de Wolf F; van der Ende ME; Hoetelmans RM; Portegies P; Danner SA
AIDS; 2000 Jul; 14(11):1583-9. PubMed ID: 10983645
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.
Piketty C; Race E; Castiel P; Belec L; Peytavin G; Si-Mohamed A; Gonzalez-Canali G; Weiss L; Clavel F; Kazatchkine MD
AIDS; 1999 Jul; 13(11):F71-7. PubMed ID: 10449277
[TBL] [Abstract][Full Text] [Related]
4. The antiviral effect of ritonavir and saquinavir in combination amongst HIV-infected adults: results from a community-based study.
Rhone SA; Hogg RS; Yip B; Sherlock C; Conway B; Schechter MT; O'Shaughnessy MV; Montaner JS
AIDS; 1998 Apr; 12(6):619-24. PubMed ID: 9583602
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study.
Yilmaz A; Fuchs D; Hagberg L; Nillroth U; Ståhle L; Svensson JO; Gisslén M
BMC Infect Dis; 2006 Mar; 6():63. PubMed ID: 16566834
[TBL] [Abstract][Full Text] [Related]
6. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. Swiss HIV Cohort Study.
Lorenzi P; Yerly S; Abderrakim K; Fathi M; Rutschmann OT; von Overbeck J; Leduc D; Perrin L; Hirschel B
AIDS; 1997 Oct; 11(12):F95-9. PubMed ID: 9342060
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens.
Hall CS; Raines CP; Barnett SH; Moore RD; Gallant JE
AIDS; 1999 Jul; 13(10):1207-12. PubMed ID: 10416524
[TBL] [Abstract][Full Text] [Related]
8. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia.
Deeks SG; Barbour JD; Grant RM; Martin JN
AIDS; 2002 Jan; 16(2):201-7. PubMed ID: 11807304
[TBL] [Abstract][Full Text] [Related]
9. Ritonavir and saquinavir combination therapy for the treatment of HIV infection.
Cameron DW; Japour AJ; Xu Y; Hsu A; Mellors J; Farthing C; Cohen C; Poretz D; Markowitz M; Follansbee S; Angel JB; McMahon D; Ho D; Devanarayan V; Rode R; Salgo M; Kempf DJ; Granneman R; Leonard JM; Sun E
AIDS; 1999 Feb; 13(2):213-24. PubMed ID: 10202827
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed.
Zolopa AR; Shafer RW; Warford A; Montoya JG; Hsu P; Katzenstein D; Merigan TC; Efron B
Ann Intern Med; 1999 Dec; 131(11):813-21. PubMed ID: 10610625
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.
Yilmaz A; Ståhle L; Hagberg L; Svennerholm B; Fuchs D; Gisslén M
Scand J Infect Dis; 2004; 36(11-12):823-8. PubMed ID: 15764168
[TBL] [Abstract][Full Text] [Related]
12. Virologic responses to a ritonavir--saquinavir-containing regimen in patients who had previously failed nelfinavir.
Tebas P; Patick AK; Kane EM; Klebert MK; Simpson JH; Erice A; Powderly WG; Henry K
AIDS; 1999 Feb; 13(2):F23-8. PubMed ID: 10202820
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 induction-maintenance at the lymph node level: the "Apollo-97" Study.
Lafeuillade A; Poggi C; Chadapaud S; Hittinger G; Chouraqui M; Delbeke E;
J Acquir Immune Defic Syndr; 2001 Oct; 28(2):154-7. PubMed ID: 11588509
[TBL] [Abstract][Full Text] [Related]
14. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure.
Deeks SG; Grant RM; Beatty GW; Horton C; Detmer J; Eastman S
AIDS; 1998 Jul; 12(10):F97-102. PubMed ID: 9677159
[TBL] [Abstract][Full Text] [Related]
15. Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1-infected individuals.
Kaufmann GR; Duncombe C; Cunningham P; Beveridge A; Carr A; Sayer D; French M; Cooper DA
AIDS; 1998 Sep; 12(13):1625-30. PubMed ID: 9764781
[TBL] [Abstract][Full Text] [Related]
16. Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.
Bickel M; Bodtländer A; Knecht GK; Stephan C; von Hentig N; Kurowski M; Gute P; Klauke S; Lutz T
J Antimicrob Chemother; 2009 Dec; 64(6):1260-4. PubMed ID: 19776037
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine.
Michelet C; Bellissant E; Ruffault A; Arvieux C; Delfraissy JF; Raffi F; Bazin C; Renard I; Sébille V; Chauvin JP; Dohin E; Cartier F
Clin Pharmacol Ther; 1999 Jun; 65(6):661-71. PubMed ID: 10391672
[TBL] [Abstract][Full Text] [Related]
18. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting.
Harrigan PR; Hertogs K; Verbiest W; Pauwels R; Larder B; Kemp S; Bloor S; Yip B; Hogg R; Alexander C; Montaner JS
AIDS; 1999 Oct; 13(14):1863-71. PubMed ID: 10513644
[TBL] [Abstract][Full Text] [Related]
19. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S
AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086
[TBL] [Abstract][Full Text] [Related]
20. Clinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients.
Marin-Niebla A; Lopez-Cortes LF; Ruiz-Valderas R; Viciana P; Mata R; Gutierrez A; Pascual R; Rodriguez M
Antimicrob Agents Chemother; 2007 Jun; 51(6):2035-42. PubMed ID: 17371813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]